Last €61.63 EUR
Change Today +1.16 / 1.92%
Volume 0.0
82P On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:00 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

pacira pharmaceuticals inc (82P) Snapshot

Open
€62.71
Previous Close
€60.47
Day High
€62.71
Day Low
€61.63
52 Week High
07/4/14 - €70.16
52 Week Low
08/2/13 - €22.66
Market Cap
2.2B
Average Volume 10 Days
29.1
EPS TTM
--
Shares Outstanding
35.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PACIRA PHARMACEUTICALS INC (82P)

Related News

No related news articles were found.

pacira pharmaceuticals inc (82P) Related Businessweek News

No Related Businessweek News Found

pacira pharmaceuticals inc (82P) Details

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures pharmaceutical products primarily for use in hospitals and ambulatory surgery centers worldwide. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company commercializes EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for administration into the surgical site to produce postsurgical analgesia; and DepoCyt(e), a liposomal formulation of the chemotherapeutic agent cytarabine indicated for the intrathecal treatment of lymphomatous meningitis, a cancer of the immune system. Its product pipeline comprise EXPAREL that has completed Phase III clinical trials for postsurgical analgesia-nerve block administration; DepoNSAID, which is in preclinical trials for the relief of acute pain; and DepoMethotrexate, an oncology preclinical candidate, as well as Bupivacaine Liposome Injectable Suspension for veterinary postsurgical analgesia. Pacira Pharmaceuticals, Inc. has a development and commercialization agreement, and related supply agreement with Aratana Therapeutics, Inc. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.

308 Employees
Last Reported Date: 02/25/14
Founded in 2006

pacira pharmaceuticals inc (82P) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $916.2K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $468.4K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $458.9K
Chief Medical Officer
Total Annual Compensation: $367.6K
Principal Accounting Officer and Executive Di...
Total Annual Compensation: $288.4K
Compensation as of Fiscal Year 2013.

pacira pharmaceuticals inc (82P) Key Developments

Pacira Pharmaceuticals, Inc. Announces Publication of Pooled Results from IMPROVE Studies Evaluating Health Economic Benefits of EXPAREL

Pacira Pharmaceuticals, Inc. announced results from a pooled analysis of IMPROVE, a series of open-label prospective, Phase 4 clinical studies designed to compare postsurgical narcotic use and health economic outcomes associated with EXPAREL (bupivacaine liposome injectable suspension) as the foundation of a multimodal analgesic regimen versus a standard opioid-based pain management regimen. The analysis, published in this month's issue of the Journal of Pain Research, concluded that in comparison to the current standard of care, an EXPAREL-based multimodal regimen was associated with significant reductions in opioid consumption, incidence of opioid-related adverse events (ORAEs), length of hospital stay and total hospital costs. The IMPROVE studies were conducted at 13 centers and evaluated a total of 191 patients, who underwent three frequently performed gastrointestinal surgeries: open colectomy, laparoscopic colectomy and ileostomy reversal. Of the 191 patients included in the analysis, 105 received an opioid-based analgesic regimen via intravenous (IV) patient-controlled analgesia (PCA), while 86 patients received an EXPAREL-based multimodal pain management regimen. According to the analysis, the EXPAREL group was associated with: A 60% reduction in total narcotic consumption (38 mg versus 96 mg in the IV opioid PCA group; P < 0.0001). A 67% reduction in incidence of ORAEs (9% versus 27% in the IV opioid PCA group; P = 0.0027). A 1.4 day reduction in median length of hospital stay (2.9 versus 4.3 days in the IV opioid PCA group; P < 0.0001). A $2,455 savings in mean per-patient hospitalization costs ($8,271 versus $10,726 for the IV opioid PCA group; P = 0.0109).

Pacira Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-02-2014 11:00 AM

Pacira Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-02-2014 11:00 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: David M. Stack, Chairman, Chief Executive Officer and President.

Pacira Pharmaceuticals, Inc. Presents at Goldman Sachs 35th Annual Global Healthcare Conference, Jun-11-2014 10:40 AM

Pacira Pharmaceuticals, Inc. Presents at Goldman Sachs 35th Annual Global Healthcare Conference, Jun-11-2014 10:40 AM. Venue: Terranea Resort in Rancho Palos Verdes, 100 Terranea Way, Los Angeles, California, United States. Speakers: David M. Stack, Chairman, Chief Executive Officer and President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
82P:GR €61.63 EUR +1.16

82P Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $48.38 USD +0.58
Cumberland Pharmaceuticals Inc $4.55 USD +0.05
Durect Corp $1.61 USD +0.02
Stryker Corp $84.02 USD +0.34
Teleflex Inc $106.97 USD +0.32
View Industry Companies
 

Industry Analysis

82P

Industry Average

Valuation 82P Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.3x
Price/Book 81.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 26.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PACIRA PHARMACEUTICALS INC, please visit www.pacira.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.